Navigation Links
Climate change could drive vast human migrations
Date:6/10/2009

countries reach an agreement to stem greenhouse gases during this December's United Nations Framework Convention on Climate Change. But even if this deadline is met, most scientists say some amount of climate change is now inevitable. To mitigate resulting migrations, the report recommends that nations prioritize the most vulnerable populations and invest there in defensive measures, including irrigation technology that uses less water; low-till agriculture; economic diversification; and official systems to manage natural disasters. It says nations must agree on how to resettle populations of low-lying areas, and strengthen the ability of emigrants to send remittances to those left in affected regions.

"New thinking and practical approaches are needed to address the threats that climate-related migration poses to human security and well-being," said coauthor Koko Warner, head of the UN University's Institute for Environment and Human Security.


'/>"/>

Contact: Kevin Krajick
kkrajick@ei.columbia.edu
212-854-9729
The Earth Institute at Columbia University
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Climate change goes underground
2. Opportunity for students displaced by Katrina to assess climate vulnerability of Southeast US
3. Climate -- no smoking gun for Neanderthals
4. NASA celebrates a decade observing climate impacts on health of worlds oceans
5. NASA celebrates a decade observing climate impacts on health of worlds oceans
6. University and state agencies to forecast local health effects of climate change
7. A greenhouse in order to study the impact of climate change on plants
8. European lead in reading past climates from ice cores
9. International team of scientists warns of climate changes impact on global river flow
10. Heaps of climate gas
11. Nobel Peace Prize 2007 to intergovernmental panel on climate change
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Climate change could drive vast human migrations
(Date:6/16/2015)... , June 16, 2015  With the increasing number ... remains a top concern. The recent compromise of ... need for strong authentication within government agencies. ... biometric one-time password (OTP) authenticator, has been submitted for ... 140-2 Level 3 validation for tamper proofing. ...
(Date:6/15/2015)... According to a new market research report ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) ... Natural Language Processing Market is expected to grow to ... forecast period 2015-2020. Browse 65 market ...   through 155 P ages and in-depth TOC ...
(Date:6/12/2015)... 12, 2015  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announced the ... electronically capture, analyze and identify participants of a ... This system can: , ... and subsequent sign-on process is actually the person ...
Breaking Biology News(10 mins):Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... China - BGI, the world,s largest genomic organization, today ... superior performance of RNA-Seq in predicting patient outcomes as ... by the U.S. Food and Drug Administration (FDA). The ... of the MicroArray Quality Control (MAQC), aimed at assessing ...
... Each year about 3300 Australian men die of ... men, matching the impact of breast cancer on women. ... removal of the prostate, radiation, freezing the tumour or ... are often side-effects including incontinence and impotence. Growing ...
... Mass., Nov. 2, 2011 VeCommerce Incorporated, a ... the recent completion of a management buyout from ... business as SimplySay, specializes in communications and speech ... services, insurance, and pari-mutuel wagering. ...
Cached Biology News:BGI to play a pivotal role in demonstrating the superior performance of RNA-Seq 2Starving prostate cancer 2VeCommerce Inc. Becomes SimplySay 2
(Date:7/1/2015)... N.C. and PARIS ... firm AgBiome, and Genective, key developer of biotech ... the discovery of new generations of insect control ... insect control to counter the realities of advancing ... Genective, aligning AgBiome,s unique insect control technology with ...
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical market is poised ... molecular diagnostics industry. BCC Research reveals in its new report that the market drivers ... and a growing need for better diagnostics as part of a molecular diagnostics trend. ...
(Date:7/1/2015)... BANGALORE, India , July 1, 2015  Strand ... next generation sequencing technology to empower cancer care, today ... as chief executive officer. In his expanded role as ... all strategy, business expansion and worldwide operations effective immediately.  ... Strand,s chairman and CEO since its founding in 2000, ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3
... 29 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that ... GSK ) related to the designation as a development candidate of ... the drug to Phase 2 proof-of-concept, at which time GSK has the option ... , "We ...
... LONDON , July 29, 2010 ... Dr Neill Moray Mackenzie to the role of Chief,Executive ... of executive,board level management within the biotechnology and pharmaceutical ... (an LSE,listed company), Avidex Ltd (now Immunocore) and most ...
... July 28 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ... Inc. (NASDAQ: ATHX) announced positive results from its ... cell therapy product, administered to individuals following acute ... a heart attack. The study results, which represent ...
Cached Biology Technology:Isis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease 2Isis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease 3CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 2CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 3CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 4CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 2Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 4Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 6Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 7Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 8Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 9
... White crystalline solid. PACKAGED UNDER ... Contaminants: DNases, proteases, RNases: none ... nm): ≤0.500; (100 mM, 1 cm, 280 ... Soluble in H 2 O. RTECS ...
... Genome ChIP-on-chip Microarray is specifically designed ... cerevisiae) DNA binding proteins by pairing ... microarrays. This set delivers robust hybridization ... true binding events and fewer false ...
... Salmonella genomes has allowed the development of ... pairs. The S. enterica Typhimurium (strain LT2) ... bp; 4,440 ORFs) and a plasmid, pSLT ... Sigma-Genosys have been designed to amplify all ...
... productivity and allows you to achieve a higher ... beyond traditional paper-based weighing processes into a powerful ... Control of ... PR, SR, PG-S, PG, SG, AT, MT, UMT, ...
Biology Products: